Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BURROUGHS WELLCOME NIX ANTI-LICE CREAM RINSE TREATMENT

Executive Summary

BURROUGHS WELLCOME NIX ANTI-LICE CREAM RINSE TREATMENT will be available to pharmacies by June, the company said. Burroughs Wellcome is pricing the Rx creme rinse to whslrs. at "about $6.00" for a two-ounce bottle packaged with a comb. Nix (permethrin) was approved by FDA on March 31 as a 1B drug (new molecular entity representing a modest therapeutic gain), after a review period of just over a year. Burroughs Wellcome filed the NDA in February 1985. The product is indicated for single-application treatment of infestation with the head louse and its eggs. "Retreatment for recurrences is required in less than 1% of patients since the ovicidal activity may be supplemented by residual persistence in the hair" the labeling notes. "Nix is the first head lice treatment to kill both lice and nits (eggs) and to provide protection from reinfestation for up to 14 days with a single application," the company said in a recent press release. The firm added that the product is the first pyrethroid to be formulated for human use.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel